KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBIT Margin: 2010-2025

Historic EBIT Margin for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to 3.54%.

  • Pacira BioSciences' EBIT Margin rose 8631.00% to 3.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.80%, marking a year-over-year increase of 1514.00%. This contributed to the annual value of -10.47% for FY2024, which is 2346.00% down from last year.
  • Pacira BioSciences' EBIT Margin amounted to 3.54% in Q3 2025, which was down 24.48% from 4.69% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' EBIT Margin peaked at 25.70% during Q2 2021, and registered a low of -82.77% during Q3 2024.
  • Over the past 3 years, Pacira BioSciences' median EBIT Margin value was 7.91% (recorded in 2024), while the average stood at 1.30%.
  • Per our database at Business Quant, Pacira BioSciences' EBIT Margin crashed by 9,358bps in 2024 and then spiked by 8,631bps in 2025.
  • Over the past 5 years, Pacira BioSciences' EBIT Margin (Quarterly) stood at 2.65% in 2021, then plummeted by 840bps to -5.75% in 2022, then surged by 2,405bps to 18.30% in 2023, then crashed by 511bps to 13.19% in 2024, then soared by 8,631bps to 3.54% in 2025.
  • Its EBIT Margin stands at 3.54% for Q3 2025, versus 4.69% for Q2 2025 and 1.18% for Q1 2025.